PDCD1 and renal cell adenocarcinoma: Although PD-1/PD-L1 inhibitors have demonstrated significant clinical efficacy in the treatment of RCC, the research landscape surrounding these immune checkpoint targets has not yet been systematically mapped using bibliometric approaches.